Structural Characterization of Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery (AMVAD) Formulations Prepared by Different Protocols and Their Efficacy Upon Intranasal Immunization of Mice

Patel, G. B.; Ponce, Amalia; Zhou, Hongyan; Chen, Wangxue

doi:10.1080/08982100802129232

Cited by 14 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here, we focus on a recent archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) technology for mucosal vaccines. [39][40][41] The polar membrane lipids in species of the Domain Archaea are uniquely distinct from the ester lipids (unbranched fatty acyl chains, usually unsaturated, attached at sn-1,2 glycerol carbon positions via ester bonds). Archaeal polar lipids comprise of regularly branched, 5-carbon repeating units making up the usually fully saturated (with few exceptions) isopranoid chains which are attached via ether bonds to the sn-2,3 carbons of the glycerol backbone.…”

Section: Lipid-based and Archaeal Lipid Mucosal Vaccine Adjuvant And mentioning

confidence: 99%

“…40,41 We use the term "archaeal lipid mucosal vaccine adjuvant and delivery" or the "AMVAD" acronym, to describe these structures. Unlike cochleates which are cylindrical, rolled up bilayer sheets devoid of any internal aqueous space(s), 31,36,49 AMVAD structures do contain aqueous capture volume.…”

Section: Lipid-based and Archaeal Lipid Mucosal Vaccine Adjuvant And mentioning

confidence: 99%

“…Unlike cochleates which are cylindrical, rolled up bilayer sheets devoid of any internal aqueous space(s), 31,36,49 AMVAD structures do contain aqueous capture volume. 40 The AMVAD formulations can be made with good batch to batch consistency by various methods, including simple admixing of pre-formed empty archaeosomes with soluble antigen, followed by addition of the cations. 40 We recently evaluated the potential of the AMVAD system as a mucosal adjuvant and vaccine delivery system.…”

Section: Lipid-based and Archaeal Lipid Mucosal Vaccine Adjuvant And mentioning

confidence: 99%

“…40 The AMVAD formulations can be made with good batch to batch consistency by various methods, including simple admixing of pre-formed empty archaeosomes with soluble antigen, followed by addition of the cations. 40 We recently evaluated the potential of the AMVAD system as a mucosal adjuvant and vaccine delivery system. 41 Intranasal immunization of mice with ovalbumin (OVA) formulated in AMVAD structures prepared from the total polar lipids (TPL) extract of Methanobrevibacter smithii (OVA/ AMVAD) elicited strong anti-OVA IgA responses at both local (nasal) and distal (gastrointestinal, vaginal) sites, and in sera.…”

Section: Lipid-based and Archaeal Lipid Mucosal Vaccine Adjuvant And mentioning

confidence: 99%

See 3 more Smart Citations

Recent advances in the development of novel mucosal adjuvants and antigen delivery systems

Chen¹,

Patel²,

Yan³

et al. 2010

Human Vaccines

Self Cite

View full text Add to dashboard Cite

Section: Lipid-based and Archaeal Lipid Mucosal Vaccine Adjuvant And mentioning

confidence: 99%

Section: Lipid-based and Archaeal Lipid Mucosal Vaccine Adjuvant And mentioning

confidence: 99%

Section: Lipid-based and Archaeal Lipid Mucosal Vaccine Adjuvant And mentioning

confidence: 99%

Section: Lipid-based and Archaeal Lipid Mucosal Vaccine Adjuvant And mentioning

confidence: 99%

See 2 more Smart Citations

Recent advances in the development of novel mucosal adjuvants and antigen delivery systems

Chen¹,

Patel²,

Yan³

et al. 2010

Human Vaccines

Self Cite

View full text Add to dashboard Cite

“…We recently described a novel, nonreplicating, particulate, archaeal polar lipid-based mucosal adjuvant and vaccine delivery (AMVAD) system (Patel et al 2007; Patel et al 2008). Intranasal immunization of ovalbumin (OVA) adjuvanted with the AMVAD system, but not with archaeosomes (liposomes made from archaeal polar lipids), elicited robust, sustained, memory-boostable, OVA-specific mucosal and systemic immune responses in mice (Patel et al 2007).…”

mentioning

confidence: 99%

Safety of Intranasally Administered Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery (AMVAD) Vaccine in Mice

et al. 2008

Self Cite

View full text Add to dashboard Cite

The safety profile of a recently described novel archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) system capable of eliciting robust antigen-specific mucosal and systemic immune responses was evaluated in female Balb/c mice (10/group) using ovalbumin (OVA) antigen. Mice were intranasally immunized (0, 7, and 21 days) with a vaccine comprising 1 microg OVA (0.05 mg/kg body weight) formulated in 0.04 mg total polar lipids extract (2.17 mg/kg body weight) of Methanobrevibacter smithii constituting the AMVAD system. Control groups were similarly immunized with 10-fold higher AMVAD vaccine dose (0.54 mg OVA and 21.7 mg lipid per kg), saline, 10 microg OVA in saline, or 0.04 or 0.4 mg lipid constituting empty AMVAD (no OVA) in saline, or were naive mice. Clinical signs, rectal temperature, and body weight were monitored once daily or as appropriate. Half the mice in each group were euthanized at 2 days after the first immunization. Blood was collected for clinical chemistry analyses. Major organs (heart, lungs, kidneys, liver, spleen, thymus, and brain) were examined macroscopically and histologically. The remaining mice were euthanized at 29 days and blood and organs collected for analyses as done at 2 days. Feces collected at 27 days, and sera, bile, and nasal lavage at 29 days, were assayed for antibody responses. Based on clinical symptoms, temperature, body weight changes, serum clinical chemistry, and tissue histopathology, there were no overt toxicities associated with OVA/AMVAD or empty AMVAD vaccines. There were no antibodies elicited against the lipids comprising the AMVAD system. These results demonstrate that at 10-fold excess dose of that required for vaccine efficacy, intranasally administered AMVAD vaccine appears to be relatively safe.

show abstract

Archaeal Membrane Lipids and Applications

Sprott¹

2011

Encyclopedia of Life Sciences

View full text Add to dashboard Cite

Membrane lipids of Archaea are unique and distinct from those found in Eukarya and Bacteria . The polar lipids consist of isoprenoid chains, 20–40 carbons in length and usually saturated, which are attached via stable ether bonds to the glycerol carbons at the sn ‐2,3 positions. Polar head groups differ at the genus level of diversity and consist of mixtures of glyco groups (mainly disaccharides), and/or phospho groups primarily phosphoglycerol, phosphoserine, phosphoethanolamine or phosphoinositol. Phosphocholine headgroups are rarely found. Extremely halophilic archaea are characterised by headgroups consisting of phosphoglycerolphosphate‐ O ‐methyl, and sulfated‐sugars. Some of these archaea synthesise cardiolipin analogues. The inherent stability and unique features of archaeal lipids makes them a useful biomarker for Archaea within environmental samples, including ocean sediments. The polar lipids of Archaea can be used to make liposomes (closed vesicles referred to as archaeosomes) with characteristics that are useful for applications in biotechnology. Archaeal‐like polar lipids are being synthesised to optimise the properties of archaeosomes to serve as next‐generation adjuvants and drug delivery systems. Key Concepts: Archaeol (2,3‐diphytanyl‐ sn ‐glycerol), and variations thereof, define the polar lipids of the domain of life, Archaea . The structures of polar lipids biosynthesised provide a useful taxonomic feature to assign an isolate to the Genus level of classification. New polar lipid structures are being reported as the field expands to encompass novel isolates. These unique polar and neutral isoprenyl lipids can be used as biomarkers of archaea in environmental samples. Archaeal lipids can serve as a rich source for novel molecules not commonly found in nature, such as β‐ l ‐gulose. Archaeal polar lipid mixtures hydrate to form lipid membrane vesicles (archaeosomes) with bilayer, unilayer or a combination of uni and bilayer structure. Archaeosomes are generally nonfusogenic in vitro , but fusion can be dramatic for certain compositions by exposure to the combination of acidic pH, calcium and glycosidase. Archaeosomes function as safe vaccine adjuvants in mammals imparting long‐lasting CD8 + T‐cell immunity and antibody responses. Isoprenoid lipids that retain the key archaeal‐lipid features are being synthesised to optimise their properties as vaccine adjuvants and delivery systems.

show abstract

Structural Characterization of Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery (AMVAD) Formulations Prepared by Different Protocols and Their Efficacy Upon Intranasal Immunization of Mice

Cited by 14 publications

References 25 publications

Recent advances in the development of novel mucosal adjuvants and antigen delivery systems

Recent advances in the development of novel mucosal adjuvants and antigen delivery systems

Safety of Intranasally Administered Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery (AMVAD) Vaccine in Mice

Archaeal Membrane Lipids and Applications

Contact Info

Product

Resources

About